AUTHORS
Cecily Allen, MD, Claudia Ansell-Paszek2, Dhananjay Vaidya, MBBS, MPH, PhD3, Shruti Chaturvedi Jr, MBBS, MS4
AFFILIATIONS
1 National Institutes of Health, Bethesda, Maryland, United States
2 Johns Hopkins University, Baltimore, Maryland, United States
3 Johns Hopkins University, Baltimore, Maryland, United States
4 Johns Hopkins University, Baltimore, Maryland, United States
ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by diagnostic complexity that frequently results in treatment delays. Terminal complement inhibitors are the cornerstone of aHUS therapy. Emerging evidence indicates that early initiation of eculizumab, defined as within 7 days of symptom onset, is associated with higher rates of renal remission compared to later initiation. However, whether an even earlier treatment threshold of less than 72 hours from symptom onset confers additional benefit to patient outcomes remains unknown. This study aims to evaluate the impact of ultra-early eculizumab initiation on medium-term renal and hematologic outcomes in patients with aHUS.
We conducted a retrospective chart review of adult patients ≥18 years of age admitted to Johns Hopkins Hospital from 2013-2022. Patients were included if they had a diagnosis of aHUS defined by: TMA and end organ damage with ADAMTS13 activity > 20% and no other evident cause for TMA. Patients without available laboratory testing (lactate dehydrogenase (LDH), complete blood count, creatinine) at diagnosis and following administration of eculizumab were excluded. Renal recovery was defined as end stage kidney disease free at 6 months or ability to achieve dialysis independence. Hematologic recovery was defined as platelet count normalization (≥150X109/L) and LDH ≤ ULN sustained for at least 2 consecutive measurements, which span a period of ≥4 weeks. TMA-event–free status: absence of all the following for ≥12 consecutive weeks: (1) a decrease in platelet count of >25%, (2) plasma exchange/infusion, and (3) new dialysis.
A total of 26 patients with aHUS were included in the analysis, of whom 19 (73%) received eculizumab within 72 hours of symptom onset (early group) and 7 (27%) received eculizumab after 72 hours (late group). The mean age in the early group was 29.5 ± 9.2 years. The majority of patients in both groups were female (79% vs. 71%, p=1.00). Baseline hemodynamic parameters were similar between groups, with no significant difference in blood pressure. Plasma exchange was utilized in 53% of the early group and 29% of the late group (p=0.39). Patients in the early group presented with a higher serum creatinine at admission compared to the late group (4.9 ± 2.6 vs. 1.5 ± 0.6 mg/dL, p=0.010). Admission platelet counts, hemoglobin, and LDH were not significantly different between groups, though hemoglobin trended lower in the early group (8.6 ± 2.0 vs. 10.5 ± 2.4 g/dL, p=0.084). Patients in the early group had significantly shorter times to hematology consultation (0.0 [IQR 0.0–1.0] vs. 5.0 [IQR 0.0–7.0] days, p=0.017) and nephrology consultation (0.0 [IQR 0.0–1.0] vs. 2.5 [IQR 1.0–3.0] days, p=0.007).
Regarding clinical outcomes, hemodialysis was required in 58% of the early group and 71% of the late group during admission (p=0.67), with 32% and 43% remaining on hemodialysis at discharge, respectively (p=0.66). Renal recovery was achieved in 68% of early versus 43% of late group patients (p=0.37), with a median time to renal recovery of 183.0 (IQR 149.0–234.0) vs. 221.0 (IQR 105.0–249.0) days (p=0.58). Hematologic recovery occurred in 74% vs. 57% of patients (p=0.64), with a median time to recovery of 92.0 (IQR 71.0–132.0) vs. 114.0 (IQR 71.0–210.0) days (p=0.73), respectively. No statistically significant differences in time to renal or hematologic outcomes were observed between groups.
Ultra-early initiation of eculizumab within 72 hours of symptom onset was associated with numerically higher rates of renal and hematologic recovery compared to later initiation. Despite presenting with more severe renal impairment at baseline, ultra-early treated patients achieved comparable or superior outcomes, suggesting a potential benefit of ultra-early complement inhibition in aHUS. Earlier specialist consultation was significantly associated with earlier treatment initiation. Our analysis was limited by few patients receiving treatment at > 72 hours reflecting institutional practice and limited availability of same day ADAMTS13 testing. Larger prospective studies are warranted to validate these findings.
DISCLOSURES
Cecily Allen, MD: No relevant conflicts of interest to declare.